CERo Therapeutics Holdings, Inc.

CERo Therapeutics Holdings, Inc. is an immunotherapy company focused on developing next-generation engineered T cell therapeutics for the treatment of cancer. The company's mission is to discover, translate, and deliver pioneering curative cell therapies that integrate multiple forms of tumor clearance into single T cells. Headquartered in South San Francisco, California, CERo Therapeutics aims to harness the body's immune system to combat cancer.

The company's core technology involves a proprietary approach to T cell engineering, which integrates desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, creating Chimeric Engulfment Receptor T cells (CER-T). Its lead product candidate, CER-1236, is an autologous T-cell therapy designed to target a novel tumor antigen, TIM-4 ligand. This platform is being developed for the treatment of both hematologic malignancies and solid tumors.

Led by CEO Chris Ehrlich, CERo Therapeutics Holdings, Inc. is publicly traded on the OTC Markets under the ticker OTCPK:CERO. Recent developments include clinical updates from the CERTAIN-T Phase 1 trial for CER-1236, with the company having completed dosing in the second ascending dose cohort and initiated the third. The company also recently secured funding from SRx Health Solutions Inc.